Patient Rating:

4.7 out of 5

70 Patient Ratings
24 Patient Comments

Ignacio Garrido-Laguna, M.D., Ph.D.

Specialties

Languages

  • English
  • Spanish

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 213-4266 Huntsman Cancer Hospital
Clinic 1A, GI/Phase I
1950 Circle of Hope
Salt Lake City, UT 84112
Map
(801) 585-0193 Huntsman Cancer Hospital
Clinic 1A, Head & Neck
1950 Circle of Hope
Salt Lake City, UT 84112
Map

Bio

Ignacio Garrido-Laguna, MD

Assistant Professor, University of Utah School of Medicine

Ignacio Garrido-Laguna, MD is an assistant professor of oncology at the University of Utah School of Medicine and a Huntsman Cancer Institute (HCI) investigator. At HCI, he sees patients with gastrointestinal cancers and patients enrolled in Phase I trials.

At HCI, Garrido-Laguna’s primary research interest is pancreatic ductal adenocarcinoma (PDA), which is the most common form of pancreatic cancer. Through his research, he has found that stroma (tissue around the tumor that gives nutrition to cancer cells) is involved in resistance to chemotherapy. He and his lab are expanding their research in order to understand what role stroma plays and what drugs can stop its negative reaction to the therapy. They intend to use this information to help identify more effective treatments for PDA.

Before joining HCI, Garrido-Laguna was a clinical fellow in the Phase I program at the University of Texas MD Anderson Cancer Center. He completed his postdoctoral fellowship in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Garrido-Laguna finished his internship and residency in medical oncology at Hospital Universitario 12 de Octubre in Madrid, Spain. Garrido-Laguna received his medical degree from the School of Medicine of Universidad de Navarra, Pamplona, Spain.

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor
Academic Divisions Oncology
Board Certification National Board of Medical Examiners
Cancer Center Programs Experimental Therapeutics

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
4.6
My confidence in care provider
4.7
Time care provider spent with me
4.6
Care provider spoke using clear language
4.7
Care provider's effort to include me in decisions
4.6
Care provider's concern for questions & worries
4.6
Care provider's explanation of condition/problem
4.7
Wait time at clinic
4.2
Care provider's friendliness and courtesy
4.8

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

July 05, 2014

Dr. Garrido gave good information about various subjects concerning me. He said he would study the last colonoscopy and let me know if 1, 2, or 3 years would be an appropriate time to wait for the next one. I thank him for that especially.

February 17, 2014

Long delay between appointment time and when the doctor showed up precluded much needed discussion. Doctor wanted another test and rushed me off to that. The only time worth anything belongs to the doctor regardless of the patient expense and travel difficulty.

February 11, 2014

please notice i chose poor for almost every rating on this page.

December 31, 2013

Everyone was very patient with the problems I was experiencing during this visit.

December 05, 2013

Couldn't ask for any more.

October 01, 2013

Dr. Garrido and his staff are great. The show compassion, are understanding and patient with her. We could not have been placed with a finer doctor.

September 09, 2013

this is the best place to be if your sick.

August 10, 2013

Provider's perceived caring and concern have been difficult to tolerate. However, he is in his professional practice very bright, skilled and knowledgeable. Therefore, I would not hesitate to recommend him to a potential patient who doesn't need a high degree of gentle and kind aspects in their care.

August 07, 2013

Although I was late on my appointment, my provider was very understanding, friendly and very informative about my medical follow up.

May 14, 2013

Dr. "G", explained details to me.

May 07, 2013

Wonderful, knowledgeable, carrying, and informative about all our concerns

April 29, 2013

Every time I go for my follow up about my condition, the provider was very friendly and informative about my health.

April 09, 2013

Dr. Garrido, is very thorough and patient, taking time every visit to review everything with me and always asking for information from me, how i feel, what more can he do for me, i feel very fortunate to have Dr. Garrido as my physician

March 12, 2013

My doctor is excellent

February 25, 2013

very personable

February 12, 2013

All care was outstanding

January 30, 2013

I was extremely impressed with everything.

January 28, 2013

trouble understanding him.. I have a hearing problem and he spoke with an accent

January 22, 2013

I was very happy with the visit.

January 21, 2013

Like the doctor but the pa didn't seem to listen I think it was because of the long wait time and her not knowing the case

December 26, 2012

I like the doctors

November 12, 2012

Our visit was cut a little short due to having to go to tumor board. Dr. Gerido explained that, and invited us to come back after he was done to further answer any questions. I didn't have a lot (of questions), but I was very impressed by this. He was very caring and concerned.

October 01, 2012

The doctor, nurse, and assistant were kind, helpful, and efficient.

June 04, 2012

when you are facing cancer... or for that matter, this care provider gives a complete picture of the care needed and is totally thorough in the matter of taking time to meticulously cover every detail of patient diagnosis, prognosis, and support care etc.

Academic Profile

Research Interests

  • Early Drug Development
  • High-throughput Techniques
  • Clinical Trials, Phase I
  • Colon Cancer
  • Pancreatic cancer
  • Preclinical models of cancer as platforms for drug development

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor
Academic Divisions Oncology
Board Certification National Board of Medical Examiners
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 585-0255 Huntsman Cancer Institute
Oncology
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Ignacio Garrido-Laguna, MD

Assistant Professor, University of Utah School of Medicine

Ignacio Garrido-Laguna, MD, is an assistant professor of oncology at the University of Utah School of Medicine, a Huntsman Cancer Institute (HCI) investigator, and a member of the Experimental Therapeutics program. At HCI, he sees patients with gastrointestinal cancers and patients enrolled in Phase I trials.

At HCI, Garrido-Laguna’s primary research interest is pancreatic ductal adenocarcinoma (PDA), which is the most common form of pancreatic cancer. Through his research, he has found that stroma (tissue around the tumor that gives nutrition to cancer cells) is involved in resistance to chemotherapy. He and his lab are expanding their research in order to understand what role stroma plays and what drugs can stop its negative reaction to the therapy. They intend to use this information to help identify more effective treatments for PDA.

Before joining HCI, Garrido-Laguna was a clinical fellow in the Phase I program at the University of Texas MD Anderson Cancer Center. He completed his postdoctoral fellowship in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Garrido-Laguna finished his internship and residency in medical oncology at Hospital Universitario 12 de Octubre in Madrid, Spain. Garrido-Laguna received his medical degree from the School of Medicine of Universidad de Navarra, Pamplona, Spain.

Education

Education History

Type School Degree
Doctoral Training Universidad de Navarra
Validation of response to gemcitabine in freshly generated pancreatic cancer xenografts
Ph.D.
Fellowship University of Texas MD Anderson Cancer Center
Investigational Cancer Therapeutics
Clinical Fellow
Postdoctoral Fellowship The Sidney Kimmel Comprehensive Cancer at Johns Hopkins
Drug Development in Gastrointestinal Oncology
Postdoctoral Fellow
Internship/Residency Hospital Universitario 12 de Octubre, Complutense University
Medical Oncology
Intern/Resident
Professional Medical Universidad de Navarra
Medicine
M.D.

Publications

Selected Provider Publications

Journal Article

  1. Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.LID - 10.1002/cncr.28701 [doi]Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R (2014). Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.LID - 10.1002/cncr.28701 [doi]. Cancer.
  2. Epidemiology and Familial Risk of Synchronous and Metachronous Colorectal Cancer: A Population-based Study in Utah.LID - S1542-3565(14)00605-3 [pii]LID - 10.1016/j.cgh.2014.04.017 [doi]Samadder NJ, Curtin K, Wong J, Tuohy TM, Mineau GP, Smith KR, Pimentel R, Pappas L, Boucher K, Garrido-Laguna I, Provenzale D, Burt RW (2014). Epidemiology and Familial Risk of Synchronous and Metachronous Colorectal Cancer: A Population-based Study in Utah.LID - S1542-3565(14)00605-3 [pii]LID - 10.1016/j.cgh.2014.04.017 [doi]. Clin Gastroenterol Hepatol.
  3. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer.Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma S (2013). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs, 31(5), 1257-64.
  4. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R (2012). Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer, 118(5), 1422-8.
  5. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R (2012). PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol, 30(8), 777-82.
  6. Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?Garrido-Laguna I, Janku F (2012). Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity? J Clin Oncol, 30(8), 892-3.
  7. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience.Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R (2012). Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer, 11(4), 297-303.
  8. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R (2012). KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One, 7(5), e38033.
  9. PIK3CA mutations in advanced cancers: characteristics and outcomes.Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R (2012). PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget, 3(12), 1566-75.
  10. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M (2011). Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther, 10(1), 3-8.
  11. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R (2011). PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther, 10(3), 558-65.
  12. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R (2011). Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist, 16(3), 327-35.
  13. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer.Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D (2011). A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther, 10(8), 1311-6.
  14. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M (2011). Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res, 17(17), 5793-800.
  15. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD (2011). Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther, 12(7), 598-609.
  16. The inverted pyramid of biomarker-driven trials.Garrido-Laguna I, Hidalgo M, Kurzrock R (2011). The inverted pyramid of biomarker-driven trials. Nat Rev Clin Oncol, 8(9), 562-6.
  17. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R (2011). PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One, 6(7), e22769.
  18. Novel therapeutic targets in non-small cell lung cancer.Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R (2011). Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol, 6(9), 1601-12.
  19. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R (2010). Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res, 16(15), 4031-7.
  20. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M (2010). Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer, 103(5), 649-55.
  21. Response of histiocytoses to imatinib mesylate: fire to ashes.Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R (2010). Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol, 28(31), e633-6.
  22. Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer.Garrido-Laguna I, Amador ML, Ruiz J, Cortes-Funes H (2009). Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer. Clin Transl Oncol, 11(3), 183-5.
  23. New scaffolds for the design of selective estrogen receptor modulators.Martin-Santamaria S, Rodriguez JJ, de Pascual-Teresa S, Gordon S, Bengtsson M, Garrido-Laguna I, Rubio-Viqueira B, Lopez-Casas PP, Hidalgo M, de Pascual-Teresa B, Ramos A (2008). New scaffolds for the design of selective estrogen receptor modulators. Org Biomol Chem, 6(19), 3486-96.
  24. Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma?Garrido-Laguna I, Ponz M, Espinos J (2007). Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma? J Clin Oncol, 25(9), 1149; author reply 1149-51.
  25. MRI evaluation of breast cancer.Garrido-Laguna I, Fernandez Hidalgo O, Garcia Foncillas J (2007). MRI evaluation of breast cancer. N Engl J Med, 357(2), 191; author reply 193.

Book Chapter

  1. Janku F, Garrido-Laguna I, Kurzrock R (2011). Early-Phase Cancer Clinical Trials: Are the Goals Scientific of Therapeutic? In ASCO Educational Book.
  2. Garrido-Laguna I (2009). Targeted Therapies. In Ettinger DS, Donehower RC, Olsen M, Schwartz RN (Ed.), Current Cancer Therapeutics, Springer Editorial (5th).
  3. Garrido-Laguna I (2006). Emergencies in Oncology. In Manual de Diagnostico y Terapeutica Medica Hospital Universitario 12 de Octubre, (Manual of Emergency University Hospital 12 de Octubre) (6th). MSD Editorial.

Abstract

  1. Reynolds K, Juric D, Baselga J, Garrido-Laguna I, Bang, Y et al (2014). A Phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer or HER2-overexpressing metastatic breast or gastric cancer [Abstract]. J Clin Oncol 32:5s, 2014 (suppl; abstr 2517), 2014 ASCO Annual Meeting.
  2. Garrido-Laguna I, Tometich D, Hu Nan, Boucher K, Sharma S (2014). N of 1 Case Reports of Exceptional Responders Among Pancreatic Cancer Patients Enrolled in First-in-man studies from 2002 through 2012. Pancreatic Cancer: Innovation in Research and Treatment 2014 New Orleans, abst # B93 [Abstract].
  3. Shepard D, Bruce J, Garrido-Laguna I, et al (2014). Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors [Abstract]. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4596).
  4. Samadder NJ, Curtin K, Wong J, Pappas L, Tuohy T, Mineau G, Smith K, Pimentel R, Boucher K, Garrido-Laguna I, Provenzale D, Burt, R (2013). Epidemiology and Familial Risk of Synchronous and Metachronous Colorectal Cancer: A Population-based Study in Utah. Abs P599, ACG Annual Meeting, San Diego 2013 [Abstract].
  5. Janku F, Garrido-Laguna I, Velez-Bravo V et al (2013). Significant activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients [Abstract]. Blood (ASH Annual Meeting Abstracts), 122(21), 3048.
  6. Garrido-Laguna I, McGregor K, Wade M, et al (6/9/2012). Testing targeted demethylation to overcome resistance to epidermal growth factor receptor (EGFR) blocking agents in wild-type (wt) KRAS metastatic colorectal cancer patients (mCRC). 2012 ASCO Annual Meeting, Chicago, IL. (Abstract number 3057) [Abstract].
  7. Garrido-Laguna I, Kurzrock R, Falchook GS, et al (2011). Dual inhibition of VEGF pathway: Phase 1 trial of bevacizumab and cediranib in advanced solid tumors. 2011 ASCO Annual Meeting, Chicago, IL. (Abstract No: 3057) [Abstract].
  8. Garrido-Laguna I, Janku F, Falchook GS, et al (2011). KRAS mutations in colorectal cancer may predict a pattern of organ-specific metastasis. AACR 102nd Annual Meeting, April 2-6, 2011; Orlando, FL. (Abstract # 2264) [Abstract].
  9. Janku F, Garrido-Laguna I, Hong DS et al (2011). Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors. AACR 102nd Annual Meeting 2011; April 2-6, 2011; Orlando, FL (Abstract #1279) [Abstract].
  10. Janku F, Garrido-Laguna I, Tsimberidou A, et al (2011). Screening for PIK3CA Mutations, PTEN Loss and RAS/RAF mutations in Early-Phase Protocols with PI3K/mTOR Pathway Inhibitors. 2011 ASCO Annual Meeting, Chicago, IL. (Abstract No: 10507) [Abstract].
  11. Garrido-Laguna I, Janku F, Falchook GS, et al (2010). Clinical outcomes of patients with advanced head and neck tumors enrolled in phase I trials is not inferior to outcomes with last treatment line based on an FDA-approved drug. AACR 101st Annual Meeting, April 17-21, 2010, Washington, DC. (Abst #2773) [Abstract].
  12. Janku F, Tsimberidou A, Garrido-Laguna I et al (2010). Screening for PIK3CA, Ras and Raf mutations in trials with PI3K/Akt/mTOR signaling pathway inhibitors. 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics”, Berlin [Abstract].
  13. Maitra A, Rajeskhumar NV, Rudek M, Garrido-Laguna I, Laheru D, Iglesias J, Desai N, Von Hoff D, Hidalgo M (2009).

    Nab-paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic models. C246. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. C246). Boston

    [Abstract].
  14. Garrido-Laguna I, Tan AC, Villarroel MC, Angenendt M, Pastori W, Rajeshkumar NV, Ciomei M, Jimeno A, Rubio-Viqueira B, Hidalgo M (2009). Activity of PHA-848125 in pancreatic cancer xenografts is related to downregulation of S6 via p53 pathway. AACR 100th Annual Meeting in Denver (Permanent abst number 1798) [Abstract].
  15. Hidalgo M, Strawn S, Wick M, Rajeshkumar NV, Garrido-Laguna I, Sidranski D, Bruckheimer E (2009). From mice to men: Guiding cancer treatment through Personalized Tumorgraft models results in prolongued clinical responses in patients with refractory advanced cancers and discovery of novel predictive biomarkers. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A19). Boston [Abstract].
  16. Rajeshkumar NV, De Oliveira E, Ottenhof N, Garrido-LagunaI I, et al (2009). MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions in pancreatic tumor xenografts. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A251). Boston [Abstract].
  17. Villaroel MC, Tan AC, Garrido-Laguna I, Rubio-Viqueira B, De Oliveira E, Rajeshkumar NV, Jimeno A, Hidalgo M (2009). Orthotopic cancer models are better predictors of clinical response than s.c. models. AACR 100th Annual Meeting in Denver (Permanent abst number 2320) [Abstract].
  18. Janku F, Garrido-Laguna I, Hong D, Tsimberidou A, et al (2009). PIK3CA mutations in patients with advanced cancers treated in phase I clinical trials. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. B134). Boston [Abstract].
  19. Mishra A, Feldmann G, Garrido-Laguna I, Dadon T, Strock C, Bannerji R, Hidalgo M, Maitra A, Nelkin B (2009). SCH727965, a novel potent cyclin dependent kinase inhibitor, inhibits pancreatic tumor growth and Ras-mediated tumorigenic signaling. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A243). Boston [Abstract].

Clinical Trials

Video & News